Ferrara Giovanni, Arnheim-Dahlström Lisen, Bartley Karen, Janson Christer, Kirchgässler Klaus-Uwe, Levine Aaron, Sköld C Magnus
Department of Respiratory Medicine and Allergy, Karolinska University Hospital, Stockholm, Sweden.
Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
Pulm Ther. 2019 Jun;5(1):55-68. doi: 10.1007/s41030-019-0087-9. Epub 2019 Mar 5.
Data on the epidemiology of idiopathic pulmonary fibrosis (IPF) in Sweden are lacking. This study estimates the incidence and prevalence of IPF in Sweden, and describes the demographic and clinical characteristics and the overall survival of patients with IPF.
Two cohorts were studied: a national cohort of 17,247 patients with pulmonary fibrosis (ICD-10 code J84.1 with no competing diagnosis) from the Swedish National Patient Register (cohort 1 [C1]); and an electronic medical record-based regional subset of C1 comprising 1755 patients having pulmonary fibrosis and a radiology procedure (C2).
The incidence of pulmonary fibrosis in C1 ranged from 10.4 to 15.4 cases per 100,000 population per year between 2001 and 2015. The prevalence increased from 15.4 to 68.0 cases per 100,000 population per year. Patients ≥ 70 years and men had a higher incidence and prevalence of pulmonary fibrosis. Common comorbidities included respiratory infections and cardiovascular disorders. Approximately one-third of patients in each cohort were hospitalised with pulmonary fibrosis within a year of diagnosis. The median survival time from disease diagnosis was 2.6 years in C1 and 5.2 years in C2. Older patients had a higher risk of hospitalisation and mortality. Women had a better prognosis than men.
This study underscores the importance of pulmonary fibrosis as a cause of respiratory-related morbidity and mortality in Sweden. The stable incidence and increasing prevalence over time suggests longer survival. The higher morbidity and mortality in older patients highlights the importance of early case detection, diagnosis and management for better prognosis.
F. Hoffmann-La Roche, Ltd./Genentech, Inc.
瑞典缺乏特发性肺纤维化(IPF)的流行病学数据。本研究估算了瑞典IPF的发病率和患病率,并描述了IPF患者的人口统计学和临床特征以及总生存率。
研究了两个队列:一个来自瑞典国家患者登记处的全国性队列,包含17247例肺纤维化患者(国际疾病分类第十版代码J84.1,无竞争诊断)(队列1 [C1]);以及基于电子病历的C1区域子集,包含1755例患有肺纤维化且接受过放射学检查的患者(C2)。
2001年至2015年间,C1中肺纤维化的发病率为每年每10万人10.4至15.4例。患病率从每年每10万人15.4例增至68.0例。年龄≥70岁的患者和男性的肺纤维化发病率和患病率更高。常见的合并症包括呼吸道感染和心血管疾病。每个队列中约三分之一的患者在诊断后一年内因肺纤维化住院。从疾病诊断开始计算,C1的中位生存时间为2.6年,C2为5.2年。老年患者住院和死亡风险更高。女性的预后比男性好。
本研究强调了肺纤维化作为瑞典呼吸相关发病和死亡原因的重要性。发病率稳定且患病率随时间增加表明生存期延长。老年患者较高的发病率和死亡率凸显了早期病例检测、诊断和管理对改善预后的重要性。
F. Hoffmann-La Roche, Ltd./Genentech, Inc.